Rubella is generally a mild, self-limiting disease with few complications. However, if rubella is acquired in the first 12 weeks of pregnancy, it usually results in congenital rubella infection with one or more severe defects (3) . Rubella has been almost eradicated by immunization programs in many developed countries, but outbreaks among unvaccinated individuals still occur (17, 20) . Rubella also continues to circulate in many other countries with less effective immunization programs (14, 19) . There is, therefore, a continuing demand for the assessment of pregnant women who develop or have contact with rubella-like illnesses. A diagnosis of rubella is currently made by using serological techniques, and the risk to the fetus is assessed by establishing the gestational age at the time of maternal infection. There are, however, occasions when it may be difficult to estimate the risk to the fetus and techniques for prenatal diagnosis of congenital rubella might be helpful (2) . The detection of rubella-specific immunoglobulin M in fetal blood obtained at cordocentesis has been employed but is not reliable until at least 22 weeks of gestation, and even then false-negative results may be obtained (11) . Isolation of rubella virus by cell culture from samples such as chorionic villi or amniotic fluid is possible, but rubella virus isolation is extremely labor-intensive and time-consuming. Rubella virus RNA has been detected in fetal specimens by nucleic acid hybridization (8, 16, 27) , but false-negative results have been reported (16) . A potentially more sensitive technique to detect rubella virus RNA is reverse transcription (RT) followed by PCR amplification (6, 10, 15) .
Here, we describe a rapid and sensitive RT nested PCR assay (RT-PCR) for the detection of rubella virus RNA by using primers from the E1 open reading frame. We have assessed its sensitivity and specificity and compared it with virus isolation for the diagnosis of acute rubella. Our RT-PCR was also compared with virus isolation for detection of rubella virus in products of conception (POCs) obtained after confirmed primary maternal rubella infection.
MATERIALS AND METHODS

Specimens. (i) Specimens from patients with rubella-like illnesses.
Pharyngeal swabs were obtained from 19 patients with rubella-like illnesses. Sixteen were received from A. Flower (Public Health Laboratory, Leicester, United Kingdom) two were from soldiers at an army camp, and one was from a local patient. Blood samples were also collected, and rubella virus infection was confirmed by detection of rubella-specific immunoglobulin M by M antibody-capture radioimmunoassay (26) . Patients referred to the Public Health Laboratory in Leicester were also tested for evidence of recent infection with parvovirus B19 and other viral causes of rash illness.
(ii) Specimens from rubella vaccinees. Pharyngeal swabs and serum and peripheral blood mononuclear cells (PBMCs) separated on Ficoll-Paque (Pharmacia, Uppsala, Sweden) were collected from one female and five male volunteers following vaccination with RA27/3 (Almevax; Wellcome Fountation Ltd., London, United Kingdom). Prior to immunization, volunteers were shown to be rubella seronegative by latex agglutination (Rubalex; Orion Diagnostica, Espoo, Finland) and enzyme immunoassay (4) .
(iii) POCs. POCs from six women who had serologically confirmed primary rubella were obtained after termination of pregnancy. All cases were referred to our laboratory by obstetricians and virologists from within the United Kingdom; the serological diagnosis was made by the referring laboratory.
Two chorionic villus, three placental, and two fetal tissue samples from seven women who had undergone termination of pregnancy between 7 and 12 weeks of gestation for other reasons and who had no serological evidence of recent rubella infection were also tested. These control samples were not tested by cell culture.
Preparation of RNA. (i) RNAzol extraction. Total RNA was extracted from tissue samples by using RNAzol-B (Biotex Laboratories Inc., Houston, Tex.) according to the manufacturer's instructions. Briefly, small tissue fragments (approximately 10 to 100 mg) were frozen in liquid nitrogen and ground to a fine powder with a precooled mortar and pestle. The ground tissue was then resuspended in 400 to 800 l of RNAzol-B, a 1/5 volume of chloroform was added, and the solution was mixed well and centrifuged at 10,500 ϫ g for 20 minutes. After centrifugation, the upper aqueous phase was transferred to a fresh tube and an equal volume of isopropanol was added. RNA was precipitated overnight at Ϫ20ЊC, and the sample was then centrifuged at 10,500 ϫ g for 20 min. The resulting pellet was washed once in 75% (vol/vol) ethanol, vacuum dried for 20 min, resuspended in 100 to 200 l of molecular biology-grade water (Sigma Chemical Co. Ltd., Dorset, United Kingdom), and stored at Ϫ70ЊC.
(ii) Phenol extraction. Nucleic acid was extracted from pharyngeal swabs and rubella-infected cell culture supernatants by a standard phenol-chloroform extraction protocol (25) . Briefly, 500 l of sample was extracted with 500 l of phenol (Tris equilibrated; pH 8.0) and then with 500 l of chloroform. The aqueous phase was either stored at Ϫ70ЊC or oligo(dT) eluted immediately as described below.
(iii) Oligo(dT) elution. Polyadenylated RNA was isolated from total RNA extractions or from phenol-extracted pharyngeal swabs and cell culture supernatants by using oligo(dT) magnetic beads (Dynal, Wirral, United Kingdom). A 100-l volume of sample was mixed with 100 l of bead suspension in 2ϫ binding buffer ( Oligonucleotides. Table 1 shows the oligonucleotides used for RT, first-round, and nested PCR. All oligonucleotides are located within the E1 open reading frame of the rubella virus genome. Oligonucleotide R2 is based on R2 described by Ho-Terry et al. (15) . Oligonucleotides R7, R11, and R8C were designed with the aid of OLIGO 4.0 primer analysis software (National Biosciences, Inc.) and are located within well-conserved regions of the rubella virus genome (12) . The external oligonucleotides (R2 and R7) produce a 185-bp PCR product, and the internal pair (R11 and R8C) produce a 143-bp product. All oligonucleotides were produced by R & D Systems Europe Ltd., Oxon, United Kingdom.
RT. Rubella virus cDNA was generated by using the Geneamp RNA PCR kit (Perkin-Elmer, Warrington, United Kingdom). The reaction was performed in 20-l volumes containing 12.5 U of reverse transcriptase (Moloney murine leukemia virus), 1 U of Inhibit-ACE (RNase inhibitor; 5 Prime to 3 Prime, Inc., Boulder, Colo.), 3.85 M primer R7 (Table 1 ), 1 mM each deoxynucleoside triphosphate, 3 mM MgCl 2 , 50 mM KCl, 10 mM Tris-HCl (pH 8.3), and 3 l of RNA sample, either bead suspension or total RNA. The reaction mixture was overlaid with mineral oil and incubated in a thermal cycler (TR 1; Hybaid Ltd., Middlesex, United Kingdom) at 37ЊC for 10 min, 42ЊC for 30 min, 99ЊC for 7 min, and 37ЊC for 2 min, using the thermal cycler's internal block temperature control.
PCR amplification. Following RT, 80 l of PCR mix was added to each RT reaction mixture to give final concentrations of 2 mM MgCl 2 , 200 M each deoxynucleoside triphosphate, 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 0.77 M primers R2 and R7 (Table 1) , and 2.5 U of Taq polymerase (Amplitaq; PerkinElmer). The reaction mix was incubated in a thermal cycler (Omnigene; Hybaid) as follows: 95ЊC for 3 min; 40 cycles of 95ЊC for 30 s, 60ЊC for 30 s, and 72ЊC for 1 min; and 72ЊC for 5 min, using the Omnigene's in-tube thermistor temperature control.
For nested PCR, 1 l of the first-round PCR product was added to 99 l of the nested PCR mix containing 1.5 mM MgCl 2 , 200 M each deoxynucleoside triphosphate 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 0.77 M primers R11 and R8C (Table 1) , and 2.5 U of Taq polymerase (Amplitaq). The nested PCR mixture was incubated by using the same thermal cycler, temperature control, and parameters as for the initial PCR but the cycle number was reduced from 40 to 25. Ten microliters of the amplified DNA product was resolved by agarose gel electrophoresis on 2% gels and visualized by ethidium bromide staining. Amplification of a 143-bp product in the nested PCR indicated the presence of rubellaspecific RNA in the RNA sample analyzed.
Negative-control RNA extractions were performed on cell culture medium alongside each batch of test specimens. All samples were tested in duplicate on one or more occasions. Two sterile-water reagent blanks were included in each batch of 16 tubes for RT-PCR, and two further blanks were included in each run of the nested PCR. High and low positive controls were also included with each batch of specimens tested by RT-PCR (see Fig. 1 ). Precautions taken to prevent contamination of PCR mixtures were as described by Muir et al. (22) . Four separate rooms were used for reagent preparation, RNA extraction, sample addition for nested PCR, and analysis of PCR products. Positive-displacement pipette tips were used for all procedures except for the nested PCR, for which a filtered tip was used for sample addition.
Specificity of rubella virus RT-PCR. To ensure that the RT-PCR could detect different strains of rubella virus, five wild-type strains and four attenuated vaccine strains were tested. The wild-type rubella strains tested were Giguere, Thomas, KO-1, RB-1, and RN, isolated in 1964 RN, isolated in , 1966 RN, isolated in , 1967 RN, isolated in , 1976 , and 1987, respectively. Giguere originated in the United States, Thomas and RN originated in the United Kingdom, and KO-1 and RB-1 originated in Japan. The four vaccine strains tested were HPV77.DE5, Cendehill, RA27/3, and To-336 (1). Cell culture supernatants from the nine strains were phenol extracted and oligo(dT) eluted prior to RT-PCR.
RNAs from 16 other RNA viruses were tested. These viruses were echovirus 30; poliovirus 3; coxsackieviruses A9, B2, and B4; human coronaviruses OC 43 and 229E; influenza viruses A, B, and C; parainfluenza virus 1; respiratory syncytial virus; rhinovirus (untyped); mumps virus PH26; measles virus Ed6; and bovine viral diarrhea virus (a pestivirus). RNAs from Vero, RK13, BHK, RMK, HEL, and human foreskin keratinocyte cells together with human PBMC RNA and DNA were also tested to ensure that nonspecific amplification did not occur.
To demonstrate that the sequences amplified by RT-PCR were derived from rubella virus RNA, we sequenced a small portion of the nested PCR product obtained from the pharyngeal swab of patient 12 ( Table 2) .
Sensitivity of rubella virus RT-PCR. The sensitivity of the RT-PCR method was initially assessed by using a dilution series of a rubella virus (RN strain)-infected cell culture supernatant with a known titer (10 6.8 50% tissue culture infective doses [TCID 50 ]/ml). Rubella virus RNA was extracted and amplified by RT-PCR from log dilutions (10 Ϫ1 to 10
Ϫ10
) of RN-infected cell culture supernatants diluted in maintenance medium, and the sensitivity of the RT-PCR relative to virus infectivity titer was calculated. The original titer of the rubella virus-infected cell culture supernatants was determined by using an endpoint dilution assay with RK13 cells (4) .
The sensitivity of the RT-PCR was also determined by using synthetic positivesense RNA transcripts. PCR-amplified rubella virus cDNA (R2-R7) was cloned into a pCR II vector by using a TA cloning kit (Invitrogen Corp., San Diego, Calif.). RNA transcripts were generated from the pCR II vector by using T7 RNA polymerase (Promega, Southampton, United Kingdom). Synthetic RNA was DNase treated, RNAzol extracted, and quantitated spectrophotometrically to determine the copy number (91 g/ml; 7.74 ϫ 10 13 copies per ml). A log dilution series (10 Ϫ1 to 10
Ϫ14
) of the RNA transcripts was made in RNA (17 g/ml) extracted from PBMCs of patient 24 obtained prior to vaccination. The dilution series was tested with and without reverse transcriptase in order to determine the dilutions at which RNA transcripts and residual vector DNA were detectable. The sensitivity relative to RNA copies was calculated from the lowest dilution in which transcripts were detected.
Rubella virus isolation. Isolation of rubella virus from pharyngeal swabs, PBMCs, and POCs was performed as described by Best and O'Shea (4). POCs (fresh or material that had been stored at Ϫ70ЊC) were washed thoroughly with phosphate-buffered saline containing antibiotics (penicillin and streptomycin), resuspended in approximately 3 ml of serum-free maintenance medium, shaken vigorously by hand, and centrifuged at 100 ϫ g for 5 min. The supernatant was removed, and 200 l was inoculated into Vero cell cultures. PBMCs were inoculated into Vero cell cultures at 10 6 cells per tube. Pharyngeal swabs were collected in virus transport media, and 200 l of this was inoculated directly into Vero cell cultures. All specimens were cultured for 7 to 10 days, rapidly frozen and thawed, and inoculated into fresh Vero cell cultures for a further 7 to 10 days. The second-passage material was then frozen, thawed, and inoculated into a Oligonucleotides used for RT (R7), first-round PCR (R2 and R7), and nested PCR (R11 and R8C). The numbering refers to the nucleotide positions of the Therien strain of rubella virus described by Dominguez et al. (9) . Y represents C or T. 
RESULTS
Rubella virus RT-PCR. (i) Specificity.
All nine strains of rubella virus tested were detected by RT-PCR. No PCR products were generated from the RNAs of 16 other RNA viruses or RNAs from seven cell types and human PBMC DNA. Sequence data (not shown) generated from the nested PCR product from the pharyngeal swab of patient 12 (Table 2) showed 97% homology (62 of 64 bases) with the sequence of the Therien strain of rubella virus (9) . No PCR products were generated when reverse transcriptase was omitted from the reverse transcriptase mix (data not shown), indicating that only cDNA was amplified.
(ii) Sensitivity. The lowest dilution of RN strain-infected cell culture supernatant in which rubella RNA was detected was 10
Ϫ6
. This was equivalent to 0.1 TCID 50 of rubella virus. When synthetic RNA transcripts derived from cloned PCR product were tested, the lowest dilution in which RNA was detected was 10
Ϫ11
, while the 10 Ϫ5 dilution was the lowest dilution in which DNA from the vector was detected. This represents a sensitivity of approximately two RNA copies detected by RT-PCR (approximately 2 ag of synthetic RNA transcript).
Detection of rubella virus in clinical samples. (i) Pharyngeal swabs.
Fourteen of the 19 patients tested had serologically confirmed rubella. Rubella virus was isolated from 10 of 12 pharyngeal swabs (83%) from these patients with confirmed rubella, while RT-PCR detected rubella virus RNA in 12 of 14 swabs (86%) ( Table 2 ). The two other pharyngeal swabs were negative by both RT-PCR and virus isolation (patients 13 and 14; Fig. 1 ). No rubella virus RNA was detected in pharyngeal swabs from five patients in whom there was no evidence of recent rubella infection. Parvovirus B19 infections were serologically confirmed in three of these patients, one had infectious mononucleosis, and the fifth patient had hepatitis B virus infection.
Rubella virus was not detected by either RT-PCR or virus isolation in the pharyngeal swabs or PBMCs obtained between 7 and 14 days postimmunization from five male vaccinees (Table 3). Rubella virus RNA was detected by RT-PCR in the pharyngeal swab taken on day 12 and by both RT-PCR and virus isolation in the swab taken on day 14 postvaccination from a female vaccinee (patient 25). Rubella virus was not detected by RT-PCR or virus isolation in the PBMCs obtained on day 12 postvaccination from this vaccinee.
(ii) POCs. RT-PCR detected rubella virus RNA in five samples obtained at termination of pregnancy from three of six women with serologically confirmed primary rubella (Table 4) . These results agreed with the results of rubella virus isolation except that the fetal kidney sample from patient 27 was positive by cell culture but negative by RT-PCR. None of the samples from the other three women, who acquired rubella 2 weeks prior to conception and at 11 and 12 weeks of gestation, were positive by either RT-PCR or virus isolation.
No rubella virus RNA was detected in the seven samples obtained from women with no evidence of recent rubella infection.
DISCUSSION
We have demonstrated that RT-PCR is a rapid, sensitive, and specific assay for detecting rubella virus RNA in a variety of clinical samples. A definitive result can be obtained in approximately 24 h of receipt of a specimen, in contrast to virus isolation, which normally takes 3 to 4 weeks. Five different rubella virus isolates and four vaccine strains were detected by RT-PCR, and no nonspecific amplification of 16 other RNA viruses or RNAs from seven cell types occurred.
The sensitivity of this assay has been shown to be approximately two RNA copies. This is equivalent to ϳ2 ag of syn-FIG. 1. Nested PCR products in 2% agarose gel. The expected product size is 143 bp (arrow). Specimens were pharyngeal swabs from patients with rubellalike rashes (Table 2) . Lanes 1 and 20, molecular weight markers (, 1 kb); lanes 2 and 15, sterile-water control; lanes 3 and 4, patient 13; lanes 5 and 6, patient 11; lanes 7 and 8, patient 14; lanes 9 and 10, patient 9; lanes 11 and 12, patient 18; lanes 13 and 14, patient 19; lanes 16 and 17, 1:1,000 and 1:10 dilutions, respectively, of positive-control RNA (rubella virus-infected Vero cell RNA diluted in human PBMC RNA); lanes 18 and 19, water and reagent blanks, respectively, for the nested PCR. thetic RNA transcript and would be equivalent to ϳ65 ag of full-length rubella virus RNA. This sensitivity is comparable to, if not better than, the 5 fg of M33 strain rubella virus-infected Vero cell RNA reported by Eggerding et al. (10) . The sensitivity of our RT-PCR also compares favorably with an RT-PCR for enterovirus RNA described by Nicholson et al. (23) and with an RT-PCR for human immunodeficiency virus RNA transcripts described by Menza et al. (18) . The detection sensitivity of 0.1 TCID 50 derived from diluted rubella-infected cell culture supernatants with known titers suggests that RT-PCR may be more sensitive than virus isolation. This could be due to detection of nonreplicating defective virus particles in the cell culture supernatant by RT-PCR (13) . Analysis of pharyngeal swabs from patients with rubella-like illnesses by RT-PCR gave 100% correlation with rubella virus isolation. In the two cases in which rubella infection was serologically confirmed but not identified by either RT-PCR or virus isolation, it is possible that virus was no longer being excreted at the time the samples were collected (6 and 7 days after onset of rash for patients 14 and 13, respectively).
PBMCs from the six vaccinees were negative by both RT-PCR and cell culture. Previously, we have isolated rubella virus from the PBMCs of 7 of 11 volunteers (64%) vaccinated subcutaneously with RA27/3 (Almevax) (24) . Although this difference in detection rates is not significant, it was noted that five of the vaccinees in the present study were male, whereas in the previous study all vaccinees were female. Mitchell et al. (21) reported that males produce earlier rubella E1-specific immunoglobulin G and M antibody responses than females following vaccination. This early antibody response, by limiting virus replication, could make it more difficult to detect virus excretion and viremia in male vaccinees. It is of interest that rubella virus was detected in the pharyngeal swabs of our female vaccinee. We are endeavoring to collect pharyngeal swabs and PBMCs from more females to investigate possible differences between male and female vaccinees.
Analysis of POCs obtained after confirmed primary maternal rubella infection gave 92% agreement (12 of 13 samples) with isolation of rubella virus by cell culture. The negative RT-PCR result obtained with the fetal kidney specimen from patient 27 may have been due to a sampling effect, as a much smaller piece of tissue was used for RT-PCR than for virus isolation. The nucleic acid concentration of the RNA extracted from the fetal kidney specimen was similar to the nucleic acid concentration of the RNA extracted from the positive lung specimen (approximately 300 g/ml). This result highlights the caution required when small tissue specimens are analyzed.
Our RT-PCR detected rubella virus RNA in 15 of 16 culture-positive specimens (sensitivity, 94%), and no false-positive results were obtained among the 29 culture-negative samples tested (specificity, 100%). These results are comparable to those reported by Ho-Terry et al. (15) . However, we tested a larger number and range of rubella isolates and clinical specimens, and we also assessed the sensitivity of our assay relative to RNA copy number. Other rubella RT-PCRs described were not used to test clinical samples (6, 10) .
As we have demonstrated that our RT-PCR is both highly sensitive and specific, we are now assessing its use for prenatal diagnosis of congenital rubella infection. RT-PCR may also be useful for investigating the role of rubella in chronic conditions such as inflammatory joint disease. In addition, by examining either fresh or archival material, the technique may help elucidate pathogenic mechanisms by which rubella induces insulin-dependent (type 1) diabetes mellitus in patients with congenitally acquired rubella (reviewed in reference 3). This may lead to a better understanding of the role of viruses in the pathogenesis of this type of diabetes.
Although significant antigenic variation has not so far been shown to occur among rubella virus strains (5), RT-PCR sequencing may be useful in monitoring sequence variation among rubella virus isolates. Until recently, measles variants had not been described, but it has now been shown that significant sequence variation has occurred among strains of measles virus isolated from young adults in the United States in 1994 (7) . It has been suggested that this phenomenon may be responsible for the occurrence of measles among persons vaccinated against measles in infancy and childhood. Similar monitoring of variation among rubella virus isolates may be important to ensure the continuing success of current rubella vaccination programs.
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